These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 22463731)
1. Mineralocorticoid receptor antagonist for renal protection. Ma TK; Szeto CC Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731 [TBL] [Abstract][Full Text] [Related]
2. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. González Monte E; Andrés A; Polanco N; Toribio MJ; Santana R; Gutiérrez Martínez E; González J; Ramírez E; Hernández A; Morales E; Praga M; Morales JM Transplant Proc; 2010 Oct; 42(8):2899-901. PubMed ID: 20970564 [TBL] [Abstract][Full Text] [Related]
3. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Sato A; Saruta T; Funder JW Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327 [TBL] [Abstract][Full Text] [Related]
5. The enhanced renin-angiotensin-aldosteron system pharmacological blockade--which is the best? Tylicki L; Lizakowski S; Rutkowski P; Renke M; Sulikowska B; Heleniak Z; Donderski R; Bednarski R; Przybylska M; Manitius J; Rutkowski B Kidney Blood Press Res; 2012; 36(1):335-43. PubMed ID: 23235363 [TBL] [Abstract][Full Text] [Related]
6. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease. Slagman MC; Navis G; Laverman GD Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849 [TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials. Fernandez-Juárez G; Barrio V; de Vinuesa SG; Goicoechea M; Praga M; Luño J J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S250-4. PubMed ID: 17130270 [TBL] [Abstract][Full Text] [Related]
9. The reno-protective effect of the dual blockade of the renin angiotensin system (RAS). Luno J; Praga M; de Vinuesa SG Curr Pharm Des; 2005; 11(10):1291-300. PubMed ID: 15853685 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway. Heerspink HJ Adv Chronic Kidney Dis; 2011 Jul; 18(4):290-9. PubMed ID: 21782135 [TBL] [Abstract][Full Text] [Related]
11. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need? Lim S Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878 [TBL] [Abstract][Full Text] [Related]
12. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Bomback AS; Toto R Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925 [TBL] [Abstract][Full Text] [Related]
13. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury? Ryan MJ; Tuttle KR Curr Opin Nephrol Hypertens; 2008 Sep; 17(5):443-9. PubMed ID: 18695383 [TBL] [Abstract][Full Text] [Related]
14. Renin-angiotensin-aldosterone system blockade for nephroprotection: current evidence and future directions. Tylicki L; Lizakowski S; Rutkowski B J Nephrol; 2012; 25(6):900-10. PubMed ID: 22684647 [TBL] [Abstract][Full Text] [Related]